 7. Subject has any clinically-significant coagulation disorder that may interfere with the assessment of efficacy or pose a safety risk to the subject according to the investigator, or baseline abnormalities of international normalized ratio INR 2.5 or activated partial thromboplastin time aPTT 100 seconds during screening that are not explained by current drug treatment e.g., warfarin, heparin 